Program Information

A Symposium held during the
Annual European Congress of Rheumatology of the European League Against Rheumatism

Friday, 14 June 2019
17:30 – 19:30

Room N117+118
Feria de Madrid
Avenida del Partenòn
28042 Madrid, Spain


17:30 – 18:00
Registration and Dinner
18:00 – 18:10
Welcome and Introductions
Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair)
18:10 – 18:20
Data from Past Educational Programs: What Do Current Gaps Mean for Patients?
Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair)
18:20 - 18:30
Panel Discussion #1:
Pathologic Mechanisms in RA and Implications for Management

All Faculty
18:30 - 18:40
Q&A Session with Attendees
18:40 - 18:50
Panel Discussion #2:
Standards for Disease Monitoring to Guide Treatment

All Faculty
18:50 - 19:00
Audience Q&A
All Faculty
19:00 - 19:20
Panel Discussion #3:
Switching versus Cycling and the Role of New Treatment Options All Faculty

All Faculty
19:20 - 19:30
Closing Remarks
All Faculty

Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair)
Arthritis Research UK Professor, Rheumatology
Director, NIHR Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds Institute of Rheumatic and Musculoskeletal Medicine
University of Leeds
Leeds, UK
Leonard H. Calabrese, DO
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Vice Chairman, Department of Rheumatic and Immunological Diseases
R. J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Ernest Choy, MD, FRCP
Professor, Head of Rheumatology and Translational Research
Division of Infection and Immunity
Director, Arthritis Research UK CREATE Centre and Welsh Arthritis Research Network (WARN)
Cardiff University School of Medicine
Cardiff, UK

Upon completion of the educational activity, participants should be able to:

  • Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA
  • Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients
  • Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs
  • Incorporate patient preferences, shared decision making, and patient education into the management plan for patients with RA

This educational activity is designed for rheumatology healthcare professionals who manage patients with RA.


An application has been made to the UEMS EACCME® for CME accreditation of this event


Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test, and submission of the activity evaluation form. A statement of credit will be available upon completion of an evaluation/claimed credit form. If you have questions about this CME activity, please contact AKH Inc. at

It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

This educational activity is supported by an independent medical educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

There is no fee for this educational activity.

Facebook  Twitter

Additional educational activities offered by RMEI Medical Education, LLC can be found
at or by calling toll-free (866) 770-RMEI.